NBB,

Yes John Carroll (Endpoints), Larry Husten (Cardiobrief) and Adam Feuerstein (Stat News) all should know about Resverlogix since they've all either written or tweeted about them in the past. It is mind boggling that one of them hasn't picked up on the BETonMACE story yet. Maybe you're right that they are still pissed about the past. BETonMACE is one of the next, if not the next, major CVOT to be finishing up and reporting data. That alone deserves attention! Then again, they may already have stories ready to go and are just waiting for the right moment, such as official announcement by Resverlogix of end of dosing and start of adjudication/follow up period.

Cabel wrote "In your opinion do you think we should be on that list,... based on what you see there,..?"

The fact that you are even asking that question is surprising based upon what we all know about the timeline and potential implications for the BETonMACE trial and apabetalone.

BearDownAZ